

Boshi Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8255109/publications.pdf>

Version: 2024-02-01

55
papers

1,440
citations

304368

22
h-index

344852

36
g-index

58
all docs

58
docs citations

58
times ranked

1536
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. <i>Drug Discovery Today</i> , 2016, 21, 118-132.	3.2	138
2	Design, Synthesis, and Evaluation of Thiophene[3,2- <i>d</i>]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7991-8007.	2.9	107
3	Structure-Based Optimization of Thiophene[3,2- <i>d</i>]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4424-4443.	2.9	79
4	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5- <i>a</i>]pyrimidine core via structure-based and physicochemical property-driven approaches. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 754-765.	2.6	76
5	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 339-350.	2.6	68
6	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2083-2098.	2.9	66
7	Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3533-3551.	2.9	60
8	Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors. <i>MedChemComm</i> , 2018, 9, 149-159.	3.5	55
9	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6379-6397.	2.9	46
10	Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. <i>Epigenomics</i> , 2015, 7, 1379-1396.	1.0	42
11	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2- <i>a</i>]pyrazines. <i>European Journal of Medicinal Chemistry</i> , 2015, 93, 330-337.	2.6	41
12	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2- <i>d</i>]pyrimidine derivatives as potent HIV-1 NNRTIs. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 878-894.	5.7	39
13	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via a "privileged scaffold" refining approach. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5182-5186.	1.0	33
14	Design of bivalent ligands targeting putative GPCR dimers. <i>Drug Discovery Today</i> , 2021, 26, 189-199.	3.2	33
15	Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities. <i>European Journal of Medicinal Chemistry</i> , 2016, 114, 65-78.	2.6	30
16	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 294-304.	2.6	28
17	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 370-375.	1.3	28
18	Teaching an old dog new tricks: Drug discovery by repositioning natural products and their derivatives. <i>Drug Discovery Today</i> , 2022, 27, 1936-1944.	3.2	28

#	ARTICLE	IF	CITATIONS
19	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 352-363.	2.6	27
20	Discovery of small molecular inhibitors targeting HIV-1 gp120â€“CD4 interaction driven from BMS-378806. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 481-490.	2.6	25
21	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. <i>Communications Chemistry</i> , 2019, 2, .	2.0	24
22	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4397-4406.	1.4	23
23	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 53-62.	2.6	21
24	Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 281-289.	2.4	21
25	Synthesis and Biological Evaluation of a Series of 2-((1- <i>H</i> -substituted-1 <i>H</i> -1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1-ylmethyl)pyrimidin-4(3 <i>H</i>)-one Potential HIV-1 Inhibitors. <i>Chemical Biology and Drug Design</i> , 2015, 86, 614-618.	1.7	17
26	Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections. <i>Chemical Biology and Drug Design</i> , 2015, 86, 568-577.	1.5	17
27	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 190-201.	2.6	17
28	Design, synthesis, and biological evaluation of piperidinyl-substituted [1,2,4]triazolo[1,5- <i>a</i>]pyrimidine derivatives as potential anti-HIV agents with reduced cytotoxicity. <i>Chemical Biology and Drug Design</i> , 2021, 97, 67-76.	1.5	16
29	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113051.	2.6	15
30	Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary. <i>Molecules</i> , 2022, 27, 850.	1.7	15
31	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions. <i>Scientific Reports</i> , 2020, 10, 20277.	1.6	14
32	Medicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment. <i>Future Medicinal Chemistry</i> , 2020, 12, 1281-1284.	1.1	14
33	Structural elucidation and in vivo anti-arthritic activity of Î²-amyryn and polpunonic acid isolated from the root bark of <i>Ziziphus abyssinica</i> HochstEx. A Rich (Rhamnaceae). <i>Bioorganic Chemistry</i> , 2020, 98, 103744.	2.0	14
34	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1348-1351.	1.0	13
35	Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. <i>Drug Discovery Today</i> , 2020, 25, 1682-1692.	3.2	13
36	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4424-4433.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach. <i>Chemical Biology and Drug Design</i> , 2016, 88, 241-253.	1.5	12
38	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. <i>European Journal of Medicinal Chemistry</i> , 2017, 140, 383-391.	2.6	12
39	The development of an effective synthetic route of lesinurad (RDEA594). <i>Chemistry Central Journal</i> , 2017, 11, 86.	2.6	11
40	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13604-13621.	2.9	10
41	Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 1271-1281.	2.5	9
42	Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 9-15.	2.4	9
43	Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419. <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 1477-1486.	2.4	8
44	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. <i>Chemical Biology and Drug Design</i> , 2016, 87, 283-289.	1.5	8
45	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7702-7723.	2.9	8
46	Design, Synthesis, and Biological Evaluation of Novel 4-Aminopiperidinyl-Linked 3,5-Disubstituted-1,2,6-thiadiazine-1,1-dione Derivatives as HIV-1 NNRTIs. <i>Chemical Biology and Drug Design</i> , 2015, 86, 107-113.	1.5	6
47	Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 5095-5112.	2.9	6
48	Facile Synthesis of Derivatives of 1,1,3-Trioxo-4,4-pyrrolo[1,2-a][1,2,4,6]thiaziazine: A New Heterocyclic System. <i>Heteroatom Chemistry</i> , 2013, 24, 495-501.	0.4	5
49	Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5-epoxy-3,14-dihydroxy-6-[(4-pyridyl)carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors. <i>Bioorganic Chemistry</i> , 2021, 109, 104702.	2.0	5
50	Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease. <i>Biomolecules</i> , 2022, 12, 696.	1.8	4
51	An improved synthesis approach of the HIV-1 inhibitor RDEA427, a pyrrolo[2,3-d]pyrimidine derivative. <i>Arkivoc</i> , 2017, 2016, 45-51.	0.3	3
52	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127287.	1.0	3
53	Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation Treatment. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4991-5003.	2.9	3
54	Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors. <i>Chemical Biology and Drug Design</i> , 2016, 88, 380-385.	1.5	2

#	ARTICLE	IF	CITATIONS
55	Effective and Versatile Synthesis of Ginkgotoxin and Its 4â€²-O-Derivatives through Regioselective 4â€²-O-Alkylation and 4â€²-O-Chlorination of 3,5â€²-O-Dibenzylpyridoxine. SynOpen, 2020, 04, 51-54.	0.8	1